Hi, this is Steve Eisman. Today I'm going to interview Mark Cuban about the healthcare industry and his private company, Cost Plus. Mark created Cost Plus to tackle a specific problem: the runaway costs of pharmaceuticals, meaning prescription drugs. His solution is to sell prescription drugs at cost plus 15%, which is a huge discount from everyone else's price. As far as I can tell, Cost Plus provides the lowest prices for drugs. I will ask him for his insights into the perverse incentives in our healthcare system and why pharmaceutical prices in the United States are just way too high. This is the third of my interviews focusing on what's wrong with our healthcare industry. Last fall, on September 22nd, I interviewed Michael Ha of Baird for a deep dive into health insurance and why it fails to adequately insure people. On January 12th of this year, I interviewed Warris Bkari, CEO of a private company called Claimable, and we explored how health insurance companies fail the people they are supposed to care for by denying way too many claims. Warris gave voice to people suffering and dying because of denials. Today I think we are going to learn a lot about how Mark is helping people by lowering drug costs and creating transparency. I also want to ask Mark about Shark Tank and the Mavericks and ask him what he learned about those experiences. And after the interview, I'll be back to summarize what I think were the most important points.
Hey, this is Steve Eisman, and welcome to another edition of The Real Eisman Playbook. And today we're going to talk healthcare, and we're going to talk about the incredible problems we're having in this country with drug pricing, with a very special guest who everybody knows: Mark Cuban. Mark Cuban, welcome to The Real Eisman Playbook.
Thanks for having me on, Steve.
So, Mark, you have a company called Cost Plus, which I'll let you describe what it is. But the purpose of the company — and I've watched several podcasts of you — is to try and help bring down drug prices, which, as we all know as a country, is an incredible problem. So, before you even talk about what your company does, and in itself it is extremely interesting, you did this for a reason, because you see a problem. So, define the problem for us. And when you're defining the problem, I also want you to address something you said in a podcast, where you said that doctors, hospitals, and other providers are being forced into the role of subprime lenders, which is part of the problem. So let's talk about the problem. Mark, you saw a problem. What's the problem?
The problem is people are okay with their doctors and trust their doctors and nurses. But when it comes to the economics of health care, everybody hates it. Nobody thinks about the cost of paying for their prescription or getting care at a hospital and thinks, 'Okay, I can afford this. This is no problem at all.' You know, it's all going to work out just fine. Everybody's terrified of that medical bill, and so many people have been saddled with incredible amounts of debt as a result of that care. And so what we set out to do was to change that, starting with pharmacy. And when you think about healthcare, when you get a prescription, the doctor doesn't say, 'Can you afford it?' or 'Here's what it's going to cost. Here's different pricing and different options.' They basically just ask you, 'Hey, what pharmacy do you use?'
Right? And they just call, and you get the drug, and then at some point you get a bill, right?
Or you have to pay your co-pay or co-insurance, or if you're underinsured or not insured, you have to pay the full price right there at the counter. Correct. And we've all seen or heard stories of somebody having to walk away because they couldn't afford their medication, or having to ration their medication, or just not even take it because they can't afford it. So we created costplusdrugs.com with the idea of: when you go to costplusdrugs.com, we want you to know exactly what your medications are going to cost. So you go to us, you put in the name of the medication. We don't carry everything, because there's some companies that still won't sell to us.
Well, you're mostly generic and biosimilars at this point.
Generic, biosimilars. And we've got a growing amount of brands, but we don't have every brand.
Where we're different is we're going to show you our actual cost. So if there's a biosimilar for Stelara, we have Stargeza, and Stelara might cost you $100,000, $120,000 a year, you know, $30,000 a quarter. With Stargeza from us, the biosimilar, it's $365 plus shipping. So when you go and it comes up, we're going to show you our actual cost. We're going to show you that we only mark it up 15%, and then you see the total price, and then we'll ship it to you. Now, you know, and that applies not just to Stargeza or Stelara, but any medication, no matter what the price.
So, your cost could literally be a tenth of what someone is paying elsewhere.
Oh, yeah. I don't want to say it always is, because they've had to respond to us. We've been in business four years, but we're almost always cheaper.
Let's press that point for a second, because I saw you on the podcast. I've spoken to a lot of people about this. Do you think that the problem rests mostly with the pharmaceutical benefit managers and the wholesale versus rebate situation? And maybe you could explain that. Is that the problem, or is it probably even broader than that?
It's much broader than that.
So, let's outline the problem.
Okay. So the problem is, and this goes back to what you're talking about, the hospitals being subprime lenders. So we all are in a set of circumstances where we have to make decisions pretty much every year about our insurance. If we get it through an employer, they'll say, here are all the different plans, and you'll pick depending on your circumstances. Do you have a family? Are you healthy? Or do you have an illness that you have to be concerned about? Whatever it may be. And you might pick a higher premium, lower deductible if you make more money, or vice versa. And if you don't have it through an employer, you may get it through the ACA, you may be on Medicaid, you may be on Medicare. But let's put aside Medicaid and Medicare, because those are government services. So if you're having to buy it for yourself, or you have to get it through an employer, your deductible ends up being more important than your premium, because if you have a deductible — if it's $1,500, which is actually a low deductible, but you can't afford $1,500. It's like if a dishwasher breaks: if you can't afford to fix it, no matter what it costs, you don't have a dishwasher. If you can't afford your deductible, you don't really have insurance.
But what happens when somebody who gets really ill goes to the hospital and can't afford their deductible? Typically, that hospital will say, 'Look, we'll loan you the money,' or, 'Here's a third party that will loan you the money.' And they know that if you can't afford a $1,500 or $2,500 or $5,000 deductible, there's a very good chance you can't pay them back. They hope you can, but they know you can't. And that basically makes them a subprime lender, where they're lending to people where the likelihood of them getting paid back isn't very high, but they do it because, A, they want to help, but more importantly, they want to get access to the insurance company money. Because even if it's a $2,500 deductible, if you need your hip replaced, you need work on your back, whatever it is, they know that once you pay your deductible, there's a good chance your insurance company is going to pay the rest, and they want to get to that money — that's why they'll loan it to you. So that's the foundation of the system, and that's where the problems start, because so many people have deductibles they can't afford. And even when there's all this talk about premium tax credits and how much higher the premiums went, still people can't afford their deductibles. We did a survey and we asked: if you're not on Medicaid or Medicare, what's more important to you, the premium or the deductible? And like 60-plus percent said the deductible.
Yeah, because that makes perfect sense. But things get worse from there. So the way the system makes things worse: the insurance companies aren't just insurance companies. The insurance companies own all these other companies, including the PBMs. Just because not everybody even knows what a PBM is — the pharmacy benefit manager. Why don't you tell people what that entity is, because there's no other country on planet Earth that has a PBM like those.
What is a PBM and what does it do?
So what a PBM does — a pharmacy benefit manager does — just what their name implies. They manage the benefits for your insurance plan. And so your insurance plan will pick any one of multiple PBMs. There's three of them that dominate and have 80-plus percent of the market. And that PBM will be responsible for setting the price that you pay during your deductible phase, setting the price you pay outside your deductible. When you get a prescription, the pharmacist puts the prescription into their software and it goes to the PBM or one of their companies, who determines if the insurance company they work with will pay for that claim.
So that's effectively what they do. And then they'll also negotiate prices with brand medications, so they'll determine how much Eliquis will be for the patient and how much the employer will pay if the employer's paying for it. So those are the basic things that they do — they manage all that. But that sounds legit, right?
Yeah, it sounds legit. The problem is they put their earnings per share way above the patient. Now, they'll disagree, obviously, but they charge rebates. They charge fees to the brand manufacturers. They may pay the manufacturer for a drug $100 and then they'll charge the employer $200, which in turn makes your premium more expensive, makes it more expensive for your boss, your employer, to pay for your insurance, right? Their insurance company — or they're part of it — will negotiate contracts with the hospital, going beyond drugs, right? And then let's just say the price they negotiate for a hip replacement is $25,000 with the local hospital, and you need a hip replacement and you just borrowed $5,000 to hit your deductible, and now you owe another $20,000 for your hip replacement that the insurance company is supposed to pay. The insurance company won't pay the full $25,000. The insurance company will underpay them. They'll short-pay them. Then they'll late-pay them. And then they'll do all these other things and audits and everything so that it becomes more expensive for the hospital to do business with your insurance company.
Which in turn makes the cost of care more expensive for everybody, because now the hospitals invent things too. So they create these things called, you know, facilities fees. Well, they'll charge you just for using the hospital.
Just for — well, yeah — for getting any type of care done. They'll jack it up. They'll do these things where if the care is offered on the fourth floor of the building and they happen to own that doctor, or that doctor works for them, they'll charge you more than if that doctor didn't work for them and was in a different office.
Right. There's a lack of transparency throughout the system, through everything. But I want to go back to the PBM because I want to talk about rebates. Just so my viewers know, there's a wonderful podcast where Mark was on with the head of Optum, who is actually a doctor, and there were times during that podcast where he said some things — which I'm going to talk about — where you literally looked like you were going to jump out of your clothing, because you already knew what he was going to say, and he said exactly what I expected, and it took everything I had to hold back. I admired you. You were really trying to control yourself.
I was trying so hard, Steve.
So, let me just tell — so, PBMs do something called rebates. There might be — they might buy a drug.
Let me explain. Let me explain.
Explain the rebate wholesale situation and how that jacks prices up, because it's so not transparent. You almost need to be able to have a dissertation to understand what these people do.
You need a PhD to figure all this stuff out. So your insurance plan that you have has something called a formulary, right? And that formulary determines which drugs your insurance plan will pay for. Now, if the insurance company and PBMs work with enough employers, they have a lot of what's called covered lives, right? And so any one insurance company PBM might cover 60 million lives. And so they go to the manufacturers of the big-name drugs, the GLP-1s, Eliquis, Xarelto, etc., and they say, 'Hey, if you want to have access to all those 60 million lives that we cover, you have to write us a check, and it's going to be called a rebate, and you're going to pay us so that you can have access to all of those members, all of those covered lives. If you don't, you're not...'
Yeah, you're not on the formulary, and we're not going to pay for it, or we're going to pay a lot less than you want to be paid. So the drug might wholesale for $1,000, the rebate might be $400. So here's the question — because this was what was on the podcast — who is paying? Is the consumer, me, you, paying $1,000 for the drug? Am I paying $600 for the drug, or am I paying somewhere in between?
So, first of all, in pharmacy, the wholesale price is the retail price, right?
It's a mess, right? That's a mess. Retail? Wholesale?
Yeah, it's a mess. They call it WAC — wholesale acquisition cost equals retail. And so, for a $1,000 retail drug, if you are in your deductible phase — so it's January, you have an ACA plan with a $5,000 deductible, right? So you have ACA silver, let's say. And that drug is $1,000. In January, when you need your prescription, you're paying $1,000.
Now you have $4,000 left on your deductible. In February, you're paying $1,000; you have $3,000, etc., etc., until you've paid off your deductible. Then they have what's called a co-pay, so it'll go down to a co-pay. And most people have had prescriptions, that's how it works for you, and you're used to this. So then it goes down to a co-pay. But regardless, the $1,000 retail price of that — there's the whole rebate amount that was negotiated that goes to the PBM. Okay?
Not to the consumer, because he said it again and again that that $400 goes to the — he basically said that the consumer pays $600. $1,000 minus $400.
No, it's just because what happens is they get control of it, and then they have these things called group purchasing organizations that they own that negotiated that rebate. That group purchasing organization will keep a vig, if you will, a fee for doing that negotiation, even though they own the company. And that fee will be 10 to 20 percent.
Yeah. Out of the thousand.
Out of the thousand. Okay. Wow. Okay.
So they'll keep $200. And so now you've got $200 left in rebate, and typically they'll pass that on to the employer, who then either keeps it or uses it to buy down the cost of premiums. But here's the messed up part, Steve: either way, however that rebate is used, that means the patient — particularly during their deductible phase — your sick patient is paying for the rebate.
The full price. Paying the $1,000.
And if $400 of that is rebate, they're paying that rebate, and then the PBM is getting it and keeping some and sending some to the employer, right? That's wrong in every way. And that's why I went nuts on him, because the idea — and most employers don't even understand this is how it works. When I talk to CEOs, benefit people, they're like, 'Oh, no, no, no, that's not it.' No, your sickest employees are the ones that pay for the rebates, by definition, because if nobody used any medications, there would be zero rebates, of course.
And so, you know, and that's just wrong. And when I tell CEOs that and they realize it, they're now starting to understand that this is a problem, and then I start to scare the hell out of them, because there's been some tragic things that have happened because of the way the system is. I was at a conference and one of the insurance brokers told a story about how there was a transportation company that had good insurance, but there was a truck driver who couldn't afford their medication during the deductible phase. Because it was a deductible, yeah, he couldn't afford the $1,000, right? So he went without. It was heart medication. The guy's driving a truck, passes out, kills four people.
A horrible tragedy. Right? All because of the way the system is designed. Now the CEO had no idea. No idea whatsoever. And so I explained this to them, like, 'Well, we can't have a system like that.' So now they're starting to understand, the ones I can talk to anyway, and they're starting to realize they have to go in a different direction and use what's called transparent pass-through PBMs, where they're not going to play these same games. They'll truly pass through the entire rebate to the employer or the patient.
Hey, Steve Eisman here. Managing a business is difficult. I know this podcast is a business. I've been running it for a year and it's been a lot of hard work. And managing a team like I do can be difficult, and overwhelming myself or my team with tedious tasks is really not helpful. So, what's a workflow you execute every week that you wish could run itself? With Notion's new custom agents, you can consider your weekly status reports handled. A status update agent can automatically scan your progress each week, synthesize key updates, and compile them into a report, and then send it out to your team so you don't have to. What a relief. Notion is an AI-powered connected workspace for teams. Notion brings all your notes, docs, and projects into one space that just works. It's seamless, flexible, powerful, and it's actually fun to use. And with AI built right in, you can spend less time switching between tools and apps and more time creating great work. And now with Notion's new custom agents, the busy work that used to take hours or never actually happened at all runs itself. Custom agents automate time-consuming, repetitive workflows directly within your Notion workspace, where your team already works and where all your knowledge already lives. Think of custom agents like AI teammates with a specific job. Whether it's a status update agent, a Q&A agent, a task routing agent, or a custom agent you've built just for your workspace, the busy work is handled. Don't take my word for it. Notion is used by over 50% of Fortune 500 companies. And some of the fastest-growing companies like OpenAI, Ramp, and Vercel use Notion AI to help their teams stay ahead. Try custom agents now at notion.com/eisman. That's all lowercase letters. notion.com/eisman to try custom agents today. And when you use our link, you're supporting our show: notion.com/eisman.
Running a company can be difficult. You have to foster a strong culture. You have to manage employees. And all that is made more difficult if you have many locations in multiple countries. Building and managing a global team can be very complicated. And when you are global, the cost of managing all those employees can be unclear, and then the fees start stacking up. Pebble brings clarity with upfront all-in hiring costs and enables you to hire the world. Pebble is an AI-powered global human resources platform built for founders, HR leaders, and operators who are hiring and supporting teams around the world. Pebble helps you hire, pay, and manage talent in over 185 countries with fast onboarding that can be done in minutes. Instead of juggling separate tools for contracts, payroll, benefits, and compliance, Pebble brings everything together with built-in guidance and local expertise to support you. This is especially helpful if you're managing teams internationally or planning to grow. The fastest-growing companies in the world use Pebble to stay organized and reduce risk. And founders use it to scale faster without feeling like they need to become HR or compliance experts. Bottom line, it simplifies global people operations so you can spend more time growing the business and supporting your team. Pebble's new standard discounted pricing at $399 per month per employee helps you contain costs. Go to hipbl.ai to get a free estimate. That's hipbl.ai for a free estimate. And if you are UK-based, sign up for Pebble for just $399 per month per employee and receive 30% off benefits. Go to hipbl.ai to get a free estimate. That's hipbl.ai for a free estimate.
So let's talk about your company. You know, when did you start it? What's its goal? How does it function? How many drugs does it have? Is it generics, biosimilars, brand name? And let's talk about something else — another part of that podcast, where you said that a lot of the pharmaceutical companies would love to work with you, right? But the insurance companies are telling them, if you work with Mark Cuban's company, we're going to cut you off. And he completely denied it like 10 times.
Yeah. Okay. So, let's just talk about your company. When did it start and how big is it now?
So we launched January 19th of 2022, and we've served millions of people since then. And I was just looking at our numbers this morning. We filled more prescriptions yesterday than we'd ever had done before in a single day. So we keep on setting records in the number of patients we support and the number of prescriptions we fill. And so we've kept on growing. In terms of numbers of drugs, we have like 5,000 SKUs, of which the number of actual drugs — because you know, a drug can have different strengths, 100 milligrams, 200 milligrams, 300 milligrams, 400 milligrams — so probably 2,200 or 2,300 drugs themselves.
Are they mostly generics or bio?
Most are generics. We have some brands — no, we have brands from Pfizer, we have brands from Bosal, we have other brands as well, and that number is growing. But as you alluded to earlier, we want to carry every drug that we possibly can, and the only reason we don't is because those big insurance companies, PBMs, they go to the big manufacturers like Lilly and others, and they say, 'Look, if you work with Cost Plus Drugs, we're not going to put you in the same position on that formulary. So instead of having access to 60 million people, you might have access to 10 million people or less,' which they know is going to cost them millions, if not hundreds of millions, if not billions of dollars across all their medications.
Just so that my viewers understand, if you're not on the insurance company's formulary, for all intents and purposes, your drug basically doesn't exist.
Right? Because the patient's insurance company is not going to pay for it. The patient's going to have to pay 100% out of pocket, which obviously most patients are not going to do. You're screwed.
You're screwed, right? And so you would think that somebody somewhere along the line just said, 'We don't care. We just want what's best for the patient.' But that doesn't happen with those big PBMs, insurance companies, and the manufacturers. I actually feel for them, because I get it. They're all public companies, and if all of a sudden they lost access to 50 million people, you know, their stock would drop by half, right? And so they tell me, 'Mark, we love what you're doing. We find little ways to work together, but on the big stuff, there's like, no, we can't do it.'
So, how have you gotten any brand name drugs to work with you, given the insurance company policy?
So the brand names we get, it's funny, are the ones where there's a competitor who paid a lot of rebate to get on the formulary. And even whether or not they were a better drug didn't matter — they paid more to get on the formulary. And so the brands that were left off the formulary, they'll come to us all the time, and so we'll sell those brands. And then there's some like VTOSA and others that are SGLT — I'm not the doctor — GLP-2s, which are weight loss drugs that are...
Like $50 a month. They won't lose you as much weight, but they'll help you lose weight. Talk to a doctor. They can prescribe it or discuss it with you. But we sell a lot of those types of brand-name medications.
So, how many lives do you now represent in terms of...
We don't really track it that way because we don't do contracts. So, you know, we've had I don't even know how many millions of customers that we've served. I just looked at our daily numbers, and as long as those numbers keep on going up, I'm happy.